corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 18996

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

LOY I
EU, India Trade Deal Could Hurt Access to Anti-Retrovirals
Scottrade Market News and Headlines 2010 Dec 15
http://research.scottrade.com/public/markets/news/news.asp?docKey=100-349w9945-1§ion=headlines&filter=COMTEX


Full text:

Every day, twice a day for the last seven years, Men Thol has swallowed a set of pills that gives him the strength to lead a normal life.

The 39-year-old tested positive for HIV in the mid-1990s. At first, he relied on traditional medicines – usually ground up tree roots mixed with other vegetables and boiled in a broth.

“They never helped,” he said. “It was so terrible before. I always needed people to help me do things.”

His health became worse and worse. One year, he developed a skin rash over his body and he grew weaker and weaker. Finally in 2003, Men was given a prescription for anti- retroviral (ARV) drugs, which are used to manage HIV. His condition stabilized and since then, he has found a steady job and lives independently.

“My whole life is better than before,” he said. “I have energy and my health is fine. Now I can help my family, instead of the other way around.”

Men is one of roughly 40,000 people living with HIV in this South-east Asian country who are on life-saving ARV treatment.

However, advocates are warning that a pending trade deal between the European Union and India – a key supplier of ARVs to the developing world – could have a disastrous effect on those who need the drugs the most.

The EU and India are negotiating a free trade agreement. But activists are worried that a pact will include crippling new restrictions on intellectual property rights that, if enforced, will severely restrict access to HIV-related drugs by making it harder and more costly for Indian companies to produce generic medication.

It is no small issue in Cambodia, a country where more than 90 percent of ARVs used are produced in India, according to Heng Phin, a program manager with Cambodian People Living with HIV/AIDS Network, an advocacy group.

“This will have a big impact for people with HIV in Cambodia,” Heng said. “In Cambodia, we cannot produce ARV drugs. We depend on the global community and developed countries.”

Statistically speaking, Cambodia has taken significant strides in reducing its HIV prevalence rate and boosting the number of people on ARVs over the last 10 years.

The prevalence rate in the adult population has gone from a peak of 2 percent in 1998, to an estimated 0.7 percent this year, reports the country’s National Aids Authority (NAA).

The number of people receiving ARV treatment has exploded over the same period. There were only 71 patients being treated in 2001, says the NAA. That number exceeded 40,000 by the middle of 2010, representing coverage of roughly 86 percent of the people who need access to such treatment.

Advocates say it is no coincidence that over that time frame, the cost of buying ARVs has plummeted thanks to generic medicine produced in India.

“In 2000, it cost 10,000 U.S. dollars per person to produce one year’s worth of ARV treatment. But now, that has been brought down to 80 dollars per person,” Heng said.

“If you think that many people in Cambodia earn under one dollar per day, you can see why we depend on generic medicine from India. If the cost is too high, then the government cannot buy it,” he added.

Cambodia is merely representative of many groups’ concern over the free trade talks.

The group Medecins sans Frontieres (MSF) says it depends on cheap generic medication to treat patients in 60 countries and that 80 percent of the HIV drugs it uses originate in India.

A report released last October by Oxfam International and Health Action International charges that the EU is “guilty of double standards”, by fighting to cut the price of medicine for European citizens, but in effect doing the opposite for people living with HIV in developing countries.

“The EU is pushing a range of (intellectual property) measures that would support the commercial interests of the pharmaceutical industry, while damaging the opportunity for innovation and access to medicines in developing countries,” the report argued.

However, the EU says any potential free trade pact will not be aimed at affecting India’s ability to export life- saving medication.

In a 2010 letter to MSF, Karel De Gucht, the European commissioner for trade, said the European Commission (EC) was “fully committed to ensuring that people in the world’s poorest countries can access affordable medicines.”

He said that details over patent terms and data exclusivity were still to be negotiated, but that the EC was “ready to show the necessary flexibility” as discussions take place. “I would like to be very clear that nothing in this agreement will prevent India from using compulsory licensing for manufacture and export of life-saving medicines to other developing countries in need,” De Gucht wrote.

But in a December statement, Anand Grover, the U.N. special rapporteur on the right to health, warned that the potential trade deal “threatens” the production of life- saving medicine.

The free trade agreement in its current form – Grover referenced “leaked texts” of a draft free trade accord in his statement – will ensure that the production of generic medicines in India will be “severely hampered”, he contended.

“Millions in the developing world depend on India for generic medicines at affordable costs,” Grover said. “Restriction of generic drug production in India will have a devastating public health impact around the world and adversely affect the right to health of millions of patients.”

EC and Indian officials say they hope to finalise an agreement by the spring of 2011.

In the meantime, people like Heng Phin worry about trickle-down effects that any pending agreement may have on him.

He is also HIV-positive. And he remembers how ARV treatment turned his life around a few years ago.

“I was very bad,” Heng recalled. “I was living in really bad conditions. My health was so poor. But after I got ARVs, then my health started getting better. I could work again.”

Said Heng: “ARVs are the best. They are like gods that help people like me. The ARVs attack the virus so my health gets better. Now, I eat well. I can do anything.”

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








You are going to have many difficulties. The smokers will not like your message. The tobacco interests will be vigorously opposed. The media and the government will be loath to support these findings. But you have one factor in your favour. What you have going for you is that you are right.
- Evarts Graham
See:
When truth is unwelcome: the first reports on smoking and lung cancer.